Who
Sanj K. Patel
Chairman & CEO
Company insider
Files Form 4 as: Chairman & CEO, Kiniksa Pharmaceuticals International; Director, Syros Pharmaceuticals; Director, BioCryst Pharmaceuticals; President & CEO, Synageva Biopharma; Director, Intercept Pharmaceuticals.
In numbers
- Trades disclosed
- 429
- Buys
- 0
- Sells
- 53
- Bought
- $0
- Sold
- $127.3M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 20 Dec 2011
- Last trade
- 1 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —9,991 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —6,481 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —9,991 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —6,481 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —6,237 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —30,050 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —120,150 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —8,609 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —6,237 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —6,481 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —9,991 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —8,609 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code F | $1.2M15,144 at $79.28 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —30,050 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —120,150 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —8,609 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —6,237 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —9,991 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —6,481 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —6,237 | filing |
News
Head to Head Review: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Zenas BioPharma (NASDAQ:ZBIO)KNSA · themarketsdaily.com · 18 Oct 2026
0 headlines in the last 90 days name Sanj K. Patel; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.